NCT04541797 (CATCH-EM) is a NA clinical trial of Empagliflozin 10 MG in Type 2 Diabetes, sponsored by The University of Hong Kong.

Who is sponsoring NCT04541797?

NCT04541797 is sponsored by The University of Hong Kong.

What drugs are being tested in NCT04541797?

Interventions in NCT04541797: Empagliflozin 10 MG, Placebo, Stress Cardiac Magnetic Resonance.

What condition does NCT04541797 study?

NCT04541797 studies Type 2 Diabetes, Microvascular Coronary Artery Disease.

Is NCT04541797 still recruiting?

NCT04541797 is currently active, enrolled. Last updated 21 November 2024.

Last reviewed 2024-11-21 · How we verify

NCT04541797: CATCH-EM

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Stress Cardiac Magnetic Resonance of Asymptomatic Type 2 Diabetics with Cardiovascular High Risk to Measure Empagliflozin Impact on Myocardial Blood Flow (CATCH-EM)

Active, enrolled NA Last updated 21 November 2024

What this trial tests

NA trial testing Empagliflozin 10 MG in Type 2 Diabetes in 160 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

1 October 2020

Primary endpoint
8 May 2024

28 February 2025

Quick facts

Lead sponsor	The University of Hong Kong
Phase	NA
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	diagnostic
Enrollment	160
Start date	1 October 2020
Primary completion	8 May 2024
Estimated completion	28 February 2025
Sites	1 location across Hong Kong

Drugs / interventions tested

Empagliflozin 10 MG — full drug profile →
Placebo
Stress Cardiac Magnetic Resonance

Conditions studied

Type 2 Diabetes — all drugs for Type 2 Diabetes →
Microvascular Coronary Artery Disease — all drugs for Microvascular Coronary Artery Disease →

Sponsor

The University of Hong Kong

Who can join

Adults 40 to 90, any sex, with Type 2 Diabetes or Microvascular Coronary Artery Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study design is a double blinded randomised control trial study that aims to conduct a randomised controlled trial of empagliflozin and determine if empagliflozin will improve myocardial blood flow in asymptomatic high risk type 2 diabetic patients. Also, to determine a cut-off using maximum upslope ratio and myocardial perfusion reserve index in which patients would demonstrate an improvement in myocardial blood flow.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Empagliflozin 10 MG

Trials testing the same drug.

NCT03867487 — SGLT2 Inhibitors as a Novel Treatment for Pediatric Non-Alcoholic Fatty Liver Disease · Phase 2 · not yet recruiting
NCT06355310 — Mechanisms of SGLT2 Inhibition in Pediatric Steatotic Liver Disease · Phase 2 · recruiting
NCT06706791 — Effect of Empagliflozin on Quality of Life in Chronic Heart Failure Patients With Diabetes Mellitus Type II · Phase 4 · recruiting
NCT06473844 — Efficacy of SGLT2 Inhibitors in Adults With Sepsis · NA · recruiting
NCT06030843 — The Treatment Effects of Empagliflozin on Renal Outcomes in Cardiorenal Syndrome Type 1 · Phase 2, PHASE3 · recruiting

Other recruiting trials for Type 2 Diabetes

Currently open trials in the same condition.

NCT07053319 — SGLT2i, Pioglitazone, and Ketone Production in T2D · Phase 1 · recruiting
NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
NCT07463859 — Effects of Periodontal Treatment Associated With Antimicrobial Photodynamic Therapy on Halitosis in Patients With Diabet · NA · recruiting
NCT07254689 — The Food for Health Study · NA · recruiting
NCT07558863 — Effect of GLP-1RA on Cardiac Autonomic Neuropathy in Type 2 Diabetes · Phase 4 · recruiting

Other The University of Hong Kong trials

Trials by the same sponsor.

NCT05981430 — Fecal Microbiota Transplantation for Decolonization of Carbapenem-resistant Enterobacteriaceae · NA · not yet recruiting
NCT07478757 — Assessing the Effectiveness of Low-Dose Computed Tomography in Lung Cancer Screening for High-Risk Smokers: A Randomized · NA · not yet recruiting
NCT07448649 — Chatbot-Assisted Advance Care Planning Education for Family Members · NA · not yet recruiting
NCT07484932 — TRTRM (ACTTOP) -Guided Dosing Strategy in Older Patients With Cancer · NA · not yet recruiting
NCT07531589 — BrainLive Connect: Non-professional Delivered CST for People Living With Dementia · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04541797 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The University of Hong Kong
Last refreshed: 21 November 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04541797.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing